Status:
UNKNOWN
Health After eaRly Menopause Due to Oophorectomy
Lead Sponsor:
The Netherlands Cancer Institute
Collaborating Sponsors:
Dutch Cancer Society
Erasmus Medical Center
Conditions:
Surgical Menopause
BRCA1 Mutation
Eligibility:
FEMALE
55+ years
Brief Summary
Risk-Reducing Salpingo-Oophorectomy (RRSO) at the age of 35 to 45 years is recommended for women with a high genetic risk for ovarian cancer. While this procedure decreases the risk of ovarian cancer ...
Detailed Description
Rationale: Women at high genetic risk of ovarian cancer are advised to undergo risk-reducing salpingo-oophorectomy (RRSO) at ages 35-45 years. Currently, in the Netherlands \~500 women/ year opt for R...
Eligibility Criteria
Inclusion
- RRSO before age 45
- RRSO after age 55
- no RRSO
Exclusion
- metastatic disease
- Premature ovarian insufficiency
- Physical or mental problems interfering with a outpatient visit
- nonbioabsorbable cardiac stent
- insufficient understanding of the Dutch language
Key Trial Info
Start Date :
February 11 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2022
Estimated Enrollment :
750 Patients enrolled
Trial Details
Trial ID
NCT03835793
Start Date
February 11 2019
End Date
January 1 2022
Last Update
September 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Netherlands Cancer Institute - Antoni van Leeuwenhoek
Amsterdam, Netherlands, 1066CX